Shannon Matheny

Articles by Shannon Matheny

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sara M. Tolaney, MD, MPH,Virginia Kaklamani, MD, DSc,Paula Muñoz Romero,Shannon Matheny,Kathy Puyana Theall,Joyce A. O’Shaughnessy

July 21st 2024

Latest Updated Articles

Trending on CancerNetwork

BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer

RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs

Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence

Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma

How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?